Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Acutus Medical, Inc. (AFIB)
USD0.00
+0.00 (+0.00%)
US OTC Healthcare Medical - Devices
Address
2210 Faraday Avenue 92008
Carlsbad, CA, US
Carlsbad, CA, US
CEO
Takeo Mukai
Website
acutusmedical.com
IPO
2020-08-06
CIK 1522860 ISIN US0051111096
Description
Acutus Medical, Inc. is a company dedicated to the treatment of cardiac arrhythmias, focusing on the design, manufacturing, and commercialization of specialized tools for catheter-based ablation procedures. These solutions are utilized to manage a spectrum of heart rhythm disorders across both domestic U.S. and international markets. The firm's extensive product offerings include innovative access sheaths, transseptal crossing devices, diagnostic and mapping catheters, along with both traditional and contact-force ablation catheters. It also provides advanced mapping and imaging consoles, accompanying accessories, and vital supporting algorithms and software. Acutus Medical, Inc. was established in 2011 and is headquartered in Carlsbad, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
4.3K
Beta
5.75
Float Shares
20.12M
Free Float %
67.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +50.00% | -40.00% | +50.00% | -99.33% | -99.96% | -100.00% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (6 ratings, all time)
Hold
Price Targets & DCF
Current price
0.00
Low
1.50
+1,499,900.0%
Consensus
1.50
+1,499,900.0%
Median
1.50
+1,499,900.0%
High
1.50
+1,499,900.0%
Ratings Trend (MoM)
0% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 1 |
1.50
+1,499,900.0%
|
Quality scores
Altman Z-Score
-28.39
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
0 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%+181.4% ★ Q4'24: +194.8% (vs Q4'23)
-
EPS growth Medical - Devices: +28.5%+88.6% ★ Q4'24: +95.9% (vs Q4'23)
-
FCF margin FCF growth · Medical - Devices: +30.9%-37.9% Q4'24: -56.3% (vs Q4'23)
-
EBIT margin Medical - Devices: +6.2%+6.1% Q4'24: +1.0% (vs Q4'23)
-
ROIC Medical - Devices: +3.3%+12.0% ★ Q4'24: +2.8% (vs Q4'23)
-
Share dilution Medical - Devices: 0.0%+2.3% Q4'24: +1.7% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×15.90× Q4'24: 27.77× (vs Q4'23)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
8.46M
est: 9.33M (-9.2%)
|
17.26M
est: 17.13M (+0.8%)
|
3.03M
est: 15.84M (-80.9%)
|
7.16M
est: 20.72M (-65.4%)
|
20.16M
est: 30.27M (-33.4%)
|
56.50M
est.
|
98.80M
98.80M – 98.80M
+74.9% YoY
|
162.50M
162.50M – 162.50M
+64.5% YoY
|
| EBITDA |
-92.55M
est: -3.04M (-2,939.9%)
|
-105.12M
est: -5.59M (-1,779.4%)
|
35.21M
est: -5.17M (+780.8%)
|
-5.33M
est: -6.76M (+21.2%)
|
2.25M
est: -9.88M (+122.8%)
|
-18.44M
est.
|
-32.25M
-32.25M – -32.25M
-74.9% YoY
|
-53.05M
-53.05M – -53.05M
-64.5% YoY
|
| EBIT |
-96.45M
est: -3.37M (-2,764.6%)
|
-112.01M
est: -6.19M (-1,710.8%)
|
34.00M
est: -5.72M (+694.4%)
|
-6.20M
est: -7.48M (+17.1%)
|
1.22M
est: -10.93M (+111.2%)
|
-20.40M
est.
|
-35.67M
-35.67M – -35.67M
-74.9% YoY
|
-58.67M
-58.67M – -58.67M
-64.5% YoY
|
| Net Income |
-101.98M
est: -159.36M (+36.0%)
|
-117.68M
est: -110.24M (-6.8%)
|
-39.62M
est: -84.84M (+53.3%)
|
-81.66M
est: -71.00M (-15.0%)
|
-9.55M
est: -46.44M (+79.4%)
|
-60.55M
est.
|
-40.19M
-40.19M – -40.19M
+33.6% YoY
|
-17.86M
-17.86M – -17.86M
+55.6% YoY
|
| SGA |
50.36M
est: 50.27M (+0.2%)
|
63.52M
est: 92.34M (-31.2%)
|
47.65M
est: 85.38M (-44.2%)
|
7.74M
est: 111.66M (-93.1%)
|
10.44M
est: 163.15M (-93.6%)
|
304.53M
est.
|
532.53M
532.53M – 532.53M
+74.9% YoY
|
875.87M
875.87M – 875.87M
+64.5% YoY
|
| EPS |
-8.94
est: -5.35 (-67.0%)
|
-4.11
est: -3.70 (-11.0%)
|
-1.39
est: -2.85 (+51.2%)
|
-2.81
est: -2.39 (-17.8%)
|
-0.32
est: -1.56 (+79.5%)
|
-1.89
est.
|
-1.35
-1.35 – -1.35
+28.6% YoY
|
-0.60
-0.60 – -0.60
+55.6% YoY
|
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-15.37M
OE per share TTM
-0.52
Owner's Yield
-172,156.87%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
103.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
17
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Deerfield Management Company, L.P. | 9.64M | 9.40% | — | 9.64M | — | 10.00 | PN | — | 2022-07-05 | ↗ |
| 2 | James E. Flynn | 9.64M | 9.40% | — | 9.64M | — | 10.00 | IN | — | 2022-07-05 | ↗ |
| 3 | Deerfield Mgmt III, L.P. | 5.73M | 5.72% | — | 5.73M | — | 10.00 | PN | — | 2022-07-05 | ↗ |
| 4 | Deerfield Private Design Fund III, L.P. | 5.73M | 5.72% | — | 5.73M | — | 10.00 | PN | — | 2022-07-05 | ↗ |
| 5 | Deerfield Mgmt, L.P. | 3.90M | 4.90% | — | 3.90M | — | 10.00 | PN | — | 2022-07-05 | ↗ |
| 6 | Deerfield Partners, L.P. | 3.90M | 4.90% | — | 3.90M | — | 10.00 | PN | — | 2022-07-05 | ↗ |
| 7 | Laurence W. Lytton | 1.75M | 11.00% | 1.75M | — | 1.75M | — | IN | USA | 2024-05-17 | ↗ |
| 8 | Shahzad Malik | 1.62M | 5.80% | 2.2K | 1.62M | 2.2K | 1.62M | IN | United Kingdom | 2022-02-14 | ↗ |
| 9 | Advent Life Sciences Fund I LP | 1.62M | 5.80% | — | 1.62M | — | 1.62M | PN | United Kingdom | 2022-02-14 | ↗ |
| 10 | Advent Life Sciences LLP | 1.62M | 5.80% | — | 1.62M | — | 1.62M | PN | United Kingdom | 2022-02-14 | ↗ |
| 11 | AMXeraya Ltd | 1.17M | 4.20% | — | 1.17M | — | 1.17M | CO | — | 2021-02-11 | ↗ |
| 12 | Fares Zahir | 1.17M | 4.20% | — | 1.17M | — | 1.17M | IN | Malaysia | 2021-02-11 | ↗ |
| 13 | Pulau Manukan Ventures Labuan Ltd. | 1.17M | 4.20% | — | 1.17M | — | 1.17M | CO | Labuan, Malaysia | 2021-02-11 | ↗ |
| 14 | 95-1411037 | 13.00 | 5.70% | 1.60M | — | 1.60M | — | IA | Delaware | 2022-02-11 | ↗ |
| 15 | Kerrisdale Advisers, LLC | — | 0.00% | — | — | — | — | IA, OO | New York | 2022-02-11 | ↗ |
| 16 | Kerrisdale Partners Master Fund, Ltd. | — | 0.00% | — | — | — | — | CO | — | 2022-02-11 | ↗ |
| 17 | Sahm Adrangi | — | 0.00% | — | — | — | — | HC, IN | Canada | 2022-02-11 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | S.A. MASON LLC | — -2.0K (-100.0%) | — -4.0 (-100.0%) | 0.00% -0.007 pp | 0.00% +0.000 pp | USD— | 17 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
3
Shares acquired
—
Shares disposed
2.13M
Cash buys
—
Cash sales
—
Net activity
-2,130,621
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-01-27 | Flynn James E | Director | D-Return | D | Warrant to Purchase Common Stock | 1,889,509 | 1.11 | 2.10M | 0 | I | ↗ |
| 2024-03-01 | Mukai Takeo | Officer | F-InKind | D | Form 4 | 8,475 | 0.21 | 1.8K | 72,874 | — | ↗ |
| 2024-02-06 | Sohn Tom | Officer | F-InKind | D | Form 4 | 7,582 | 0.17 | 1.3K | 105,009 | — | ↗ |
| 2024-02-01 | Sohn Tom | Officer | F-InKind | D | Form 4 | 5,709 | 0.19 | 1.1K | 112,591 | — | ↗ |
| 2024-02-01 | Mukai Takeo | Officer | F-InKind | D | Form 4 | 2,869 | 0.19 | 547.98 | 81,349 | — | ↗ |
| 2024-01-07 | Roman David | Officer | F-InKind | D | Form 4 | 24,086 | 0.19 | 4.6K | 332,134 | — | ↗ |
| 2024-01-07 | Mathews Kevin | Officer | F-InKind | D | Form 4 | 6,342 | 0.19 | 1.2K | 61,106 | — | ↗ |
| 2023-09-01 | Mukai Takeo | Officer | F-InKind | D | FORM 4 | 1,729 | 0.49 | 843.75 | 84,218 | — | ↗ |
| 2023-08-05 | Sohn Tom | Officer | F-InKind | D | FORM 4 | 433 | 0.69 | 298.77 | 118,300 | — | ↗ |
| 2023-08-05 | Mathews Kevin | Officer | F-InKind | D | FORM 4 | 134 | 0.69 | 92.46 | 67,448 | — | ↗ |
| 2023-08-02 | Mukai Takeo | Officer | F-InKind | D | FORM 4 | 501 | 0.00 | — | 83,447 | — | ↗ |
| 2023-08-01 | Sohn Tom | Officer | A-Award | A | FORM 4 | 20,000 | 0.00 | — | 118,733 | — | ↗ |
| 2023-08-01 | Roman David | Officer | F-InKind | D | FORM 4 | 6,484 | 0.00 | — | 356,220 | — | ↗ |
| 2023-06-15 | Sheridan John F | Director | A-Award | A | FORM 4 | 8,400 | 0.00 | — | 24,347 | — | ↗ |
| 2023-06-15 | Pellegrini Niamh Louise | Director | A-Award | A | FORM 4 | 19,600 | 0.83 | 16.4K | 19,600 | — | ↗ |
| 2023-06-15 | Marzouk Shaden | Director | A-Award | A | FORM 4 | 19,600 | 0.83 | 16.4K | 19,600 | — | ↗ |
| 2023-06-15 | Huennekens R Scott | Director | A-Award | A | FORM 4 | 10,920 | 0.00 | — | 21,840 | — | ↗ |
| 2023-06-15 | Garland Jason K | Director | A-Award | A | FORM 4 | 19,600 | 0.83 | 16.4K | 19,600 | — | ↗ |
| 2023-06-15 | Flynn James E | Director | A-Award | A | Stock Option (Right to Buy) | 19,600 | 0.83 | 16.4K | 19,600 | — | ↗ |
| 2023-06-15 | ElBardissi Andrew | Director | A-Award | A | FORM 4 | 19,600 | 0.83 | 16.4K | 19,600 | — | ↗ |
| 2023-06-15 | Bonita David P | Director | A-Award | A | FORM 4 | 8,400 | 0.00 | — | 20,822 | — | ↗ |
| 2023-06-01 | Roman David | Officer | F-InKind | D | FORM 4 | 17,290 | 0.85 | 14.7K | 362,704 | — | ↗ |
| 2023-04-01 | Sohn Tom | Officer | F-InKind | D | FORM 4 | 855 | 0.75 | 644.67 | 98,733 | — | ↗ |
| 2023-04-01 | Roman David | Officer | F-InKind | D | FORM 4 | 3,165 | 0.75 | 2.4K | 379,994 | — | ↗ |
| 2023-04-01 | Mathews Kevin | Officer | F-InKind | D | FORM 4 | 321 | 0.75 | 242.03 | 66,332 | — | ↗ |
| 2023-03-01 | Sohn Tom | Officer | A-Award | A | FORM 4 | 42,500 | 1.41 | 59.9K | 42,500 | — | ↗ |
| 2023-03-01 | Roman David | Officer | A-Award | A | FORM 4 | 135,000 | 0.00 | — | 383,159 | — | ↗ |
| 2023-03-01 | Piscitello Charlie | Officer | A-Award | A | FORM 4 | 42,500 | 1.41 | 59.9K | 42,500 | — | ↗ |
| 2023-03-01 | Mukai Takeo | Officer | A-Award | A | FORM 4 | 47,500 | 1.41 | 67.0K | 47,500 | — | ↗ |
| 2023-03-01 | Mathews Kevin | Officer | A-Award | A | FORM 4 | 42,500 | 0.00 | — | 66,653 | — | ↗ |
| 2023-02-01 | Sohn Tom | Officer | F-InKind | D | FORM 4 | 6,525 | 1.87 | 12.2K | 57,190 | — | ↗ |
| 2023-02-01 | Roman David | Officer | F-InKind | D | FORM 4 | 10,196 | 1.87 | 19.1K | 248,159 | — | ↗ |
| 2023-02-01 | Piscitello Charlie | Officer | F-InKind | D | FORM 4 | 6,627 | 1.87 | 12.4K | 44,038 | — | ↗ |
| 2023-02-01 | Mukai Takeo | Officer | F-InKind | D | FORM 4 | 2,855 | 1.87 | 5.3K | 36,448 | — | ↗ |
| 2023-02-01 | Mathews Kevin | Officer | F-InKind | D | FORM 4 | 3,540 | 1.87 | 6.6K | 24,153 | — | ↗ |
| 2022-10-01 | Huennekens R Scott | Director | A-Award | A | Common Stock | 2,520 | 0.00 | — | 10,920 | — | ↗ |
| 2022-09-01 | Mukai Takeo | Officer | A-Award | A | Common Stock | 20,000 | 0.00 | — | 39,303 | — | ↗ |
| 2022-09-01 | Garland Jason K | Director | A-Award | A | Common Stock | 14,000 | 0.00 | — | 14,000 | — | ↗ |
| 2022-08-22 | Mukai Takeo | Officer | — | D | Common Stock | 0 | 0.00 | — | 19,303 | — | ↗ |
| 2022-08-22 | Garland Jason K | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-08-05 | Sohn Tom | Officer | F-InKind | D | Common Stock | 433 | 1.56 | 675.48 | 63,613 | — | ↗ |
| 2022-08-05 | Piscitello Charlie | Officer | F-InKind | D | Common Stock | 433 | 1.56 | 675.48 | 49,415 | — | ↗ |
| 2022-08-05 | Mathews Kevin | Officer | F-InKind | D | Common Stock | 134 | 1.56 | 209.04 | 27,693 | — | ↗ |
| 2022-07-25 | Sohn Tom | Officer | D-Return | D | Employee Stock Options (Right to Buy) | 32,000 | 0.00 | — | 103,956 | — | ↗ |
| 2022-07-25 | Roman David | Officer | D-Return | D | Employee Stock Options (Right to Buy) | 50,000 | 0.00 | — | 77,335 | — | ↗ |
| 2022-07-25 | Piscitello Charlie | Officer | A-Award | A | Employee Stock Options (Right to Buy) | 32,500 | 0.00 | — | 146,740 | — | ↗ |
| 2022-07-25 | Mathews Kevin | Officer | D-Return | D | Employee Stock Options (Right to Buy) | 20,000 | 0.00 | — | 37,050 | — | ↗ |
| 2022-07-20 | Sohn Tom | Officer | — | D | Stock Options (Right to Buy) | 34,800 | 13.66 | 475.4K | 0 | — | ↗ |
| 2022-07-20 | Piscitello Charlie | Officer | — | D | Stock Options (Right to Buy) | 32,500 | 2.41 | 78.3K | 0 | — | ↗ |
| 2022-07-20 | Mathews Kevin | Officer | — | D | Stock Options (Right to Buy) | 21,583 | 18.00 | 388.5K | 0 | — | ↗ |
| 2022-06-30 | Flynn James E | Director / 10% Owner | A-Award | A | Warrant to Purchase Common Stock | 1,889,509 | 1.11 | 2.10M | 1,889,509 | — | ↗ |
| 2022-06-30 | Deerfield Private Design Fund III, L.P. | Director | A-Award | A | Warrant to Purchase Common Stock | 1,889,509 | 0.00 | — | 1,889,509 | — | ↗ |
| 2022-06-16 | Sheridan John F | Director | A-Award | A | Common Stock | 8,400 | 0.00 | — | 15,947 | — | ↗ |
| 2022-06-16 | Pellegrini Niamh Louise | Director | A-Award | A | Common Stock | 8,400 | 0.00 | — | 12,572 | — | ↗ |
| 2022-06-16 | Marzouk Shaden | Director | A-Award | A | Common Stock | 8,400 | 0.00 | — | 12,422 | — | ↗ |
| 2022-06-16 | Huennekens R Scott | Director | A-Award | A | Common Stock | 8,400 | 0.00 | — | 8,400 | — | ↗ |
| 2022-06-16 | Hinrichs James F. | Director | A-Award | A | Stock Options (Right to Buy) | 19,600 | 0.50 | 9.9K | 19,600 | — | ↗ |
| 2022-06-16 | Flynn James E | Director | A-Award | A | Stock Option (Right to Buy) | 19,600 | 0.50 | 9.9K | 19,600 | — | ↗ |
| 2022-06-16 | ElBardissi Andrew | Director | A-Award | A | Stock Options (Right to Buy) | 19,600 | 0.00 | — | 19,600 | — | ↗ |
| 2022-06-16 | Cramp Daniella | Director | A-Award | A | Common Stock | 8,400 | 0.00 | — | 11,623 | — | ↗ |
| 2022-06-16 | Bonita David P | Director | A-Award | A | Common Stock | 8,400 | 0.00 | — | 12,422 | — | ↗ |
| 2022-06-03 | Huennekens R Scott | Director | S-Sale | D | Common Stock | 60,000 | 0.58 | 34.8K | 507,509 | — | ↗ |
| 2022-06-01 | Roman David | Officer | A-Award | A | Common Stock | 100,000 | 0.00 | — | 183,355 | — | ↗ |
| 2022-04-01 | Roman David | Officer | F-InKind | D | Common Stock | 3,248 | 1.30 | 4.2K | 83,355 | — | ↗ |
| 2022-04-01 | McQuillan Steven | Officer | F-InKind | D | Common Stock | 733 | 1.30 | 952.90 | 45,844 | — | ↗ |
| 2022-04-01 | Burgess Vincent J | Officer | F-InKind | D | Common Stock | 3,896 | 1.30 | 5.1K | 61,469 | — | ↗ |
| 2022-02-01 | Roman David | Officer | A-Award | A | Common Stock | 50,000 | 0.00 | — | 86,603 | — | ↗ |
| 2022-02-01 | McQuillan Steven | Officer | A-Award | A | Common Stock | 32,000 | 0.00 | — | 46,577 | — | ↗ |
| 2021-11-15 | Hinrichs James F. | Director | P-Purchase | A | Common Stock | 40,000 | 3.78 | 151.2K | 52,911 | — | ↗ |
| 2021-08-10 | Pellegrini Niamh Louise | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-08-05 | McQuillan Steven | Officer | F-InKind | D | Common Stock | 305 | 15.52 | 4.7K | 14,577 | — | ↗ |
| 2021-08-05 | Burgess Vincent J | Director / Officer | F-InKind | D | Common Stock | 1,922 | 15.52 | 29.8K | 65,365 | — | ↗ |
| 2021-07-19 | ORBIMED ADVISORS LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 714,285 | 14.00 | 10.00M | 4,872,025 | — | ↗ |
| 2021-07-19 | Flynn James E | Director / 10% Owner | P-Purchase | A | Common Stock | 680,592 | 14.00 | 9.53M | 3,438,589 | — | ↗ |
| 2021-07-19 | Bonita David P | Director / 10% Owner | P-Purchase | A | Common Stock | 714,285 | 14.00 | 10.00M | 4,872,025 | — | ↗ |
| 2021-06-17 | Marzouk Shaden | Director | A-Award | A | Common Stock | 1,800 | 0.00 | — | 4,022 | — | ↗ |
| 2021-06-17 | Malik Shahzad | Director | A-Award | A | Stock Options (Right to Buy) | 7,022 | 16.66 | 117.0K | 7,022 | — | ↗ |
| 2021-06-17 | Hinrichs James F. | Director | A-Award | A | Common Stock | 1,800 | 0.00 | — | 12,911 | — | ↗ |
| 2021-06-17 | Flynn James E | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 7,022 | 16.66 | 117.0K | 7,022 | — | ↗ |
| 2021-06-17 | ElBardissi Andrew | Director | A-Award | A | Common Stock | 1,800 | 0.00 | — | 4,022 | — | ↗ |
| 2021-06-17 | Bonita David P | Director / 10% Owner | A-Award | A | Common Stock | 1,800 | 0.00 | — | 4,022 | — | ↗ |
| 2021-04-01 | Roman David | Officer | A-Award | A | Common Stock | 36,603 | 0.00 | — | 36,603 | — | ↗ |
| 2021-04-01 | McQuillan Steven | Officer | A-Award | A | Stock Options (Right to Buy) | 34,800 | 13.66 | 475.4K | 34,800 | — | ↗ |
| 2021-04-01 | Burgess Vincent J | Director / Officer | A-Award | A | Stock Options (Right to Buy) | 158,691 | 13.66 | 2.17M | 158,691 | — | ↗ |
| 2021-03-17 | Sheridan John F | Director | A-Award | A | Stock Options (Right to Buy) | 10,882 | 19.06 | 207.4K | 10,882 | — | ↗ |
| 2021-03-01 | Roman David | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-02-03 | McQuillan Steven | Officer | — | D | Stock Options (Right to Buy) | 89,254 | 7.68 | 685.5K | 0 | — | ↗ |
| 2021-02-03 | Cramp Daniella | Director | A-Award | A | Common Stock | 2,423 | 0.00 | — | 3,223 | — | ↗ |
| 2020-08-10 | ORBIMED ADVISORS LLC | Director / 10% Owner | C-Conversion | D | Series D Convertible Preferred Stock | 378,733 | 0.00 | — | 0 | — | ↗ |
| 2020-08-10 | Malik Shahzad | Director | C-Conversion | A | Common Stock | 1,551,713 | 0.00 | — | 1,551,713 | — | ↗ |
| 2020-08-10 | Hinrichs James F. | Director | P-Purchase | A | Common Stock | 10,000 | 18.00 | 180.0K | 11,111 | — | ↗ |
| 2020-08-10 | Flynn James E | Director / 10% Owner | P-Purchase | A | Common Stock | 555,556 | 18.00 | 10.00M | 2,758,000 | — | ↗ |
| 2020-08-10 | Bonita David P | Director / 10% Owner | P-Purchase | A | Common Stock | 41,500 | 18.00 | 747.0K | 41,500 | — | ↗ |
| 2020-08-10 | Barnickel John | Officer | P-Purchase | A | Common Stock | 7,300 | 18.00 | 131.4K | 13,966 | — | ↗ |
| 2020-08-05 | ORBIMED ADVISORS LLC | Director / 10% Owner | — | I | Series D Convertible Preferred Stock | 378,733 | 0.00 | — | 0 | — | ↗ |
| 2020-08-05 | Marzouk Shaden | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-08-05 | Malik Shahzad | Director | — | I | Series D Convertible Preferred Stock | 171,695 | 0.00 | — | 0 | — | ↗ |
| 2020-08-05 | Huennekens R Scott | Director | — | D | Common Stock | 0 | 0.00 | — | 567,509 | — | ↗ |
| 2020-08-05 | Hinrichs James F. | Director | — | D | Stock Options (Right to Buy) | 20,957 | 14.81 | 310.4K | 0 | — | ↗ |
| 2020-08-05 | Flynn James E | Director / 10% Owner | — | I | Series D Preferred Stock | 189,366 | 0.00 | — | 0 | — | ↗ |
| 2020-08-05 | ElBardissi Andrew | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-08-05 | Doherty Gary W. | Officer | — | D | Stock Options (Right to Buy) | 71,162 | 13.37 | 951.4K | 0 | — | ↗ |
| 2020-08-05 | Burgess Vincent J | Director / Officer | — | D | Stock Options (Right to Buy) | 28,946 | 8.07 | 233.6K | 0 | — | ↗ |
| 2020-08-05 | Bonita David P | Director / 10% Owner | — | I | Series B Convertible Preferred Stock | 673,123 | 0.00 | — | 0 | — | ↗ |
| 2020-08-05 | Barnickel John | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
14.4K
Shares Outstanding
29.91M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2023 | David Roman Former President and Chief Executive Officer | 491.7K | 140.0K | 190.4K | 127.5K | — | 1.6K | 951.1K | 33.42% | ↗ |
| 2 | 2023 | Kevin Mathews Former SVP, Commercial | 310.0K | — | 59.9K | 40.1K | — | 198.7K | 608.7K | 16.44% | ↗ |
| 3 | 2023 | Takeo Mukai Chief Executive Officer and Chief Financial Officer | 323.4K | 60.0K | 67.0K | 44.9K | — | 1.6K | 496.8K | 22.51% | ↗ |
| 4 | 2022 | Vince Burgess Former President and CEO | 301.5K | — | 89.7K | — | — | 810.2K | 1.20M | 7.47% | ↗ |
| 5 | 2022 | David Roman Former President and Chief Executive Officer | 419.7K | 184.0K | 291.8K | 133.0K | — | 1.2K | 1.03M | 41.26% | ↗ |
| 6 | 2022 | David Roman President and CEO | 419.7K | 184.0K | 291.8K | 133.0K | — | 1.2K | 1.03M | 41.26% | ↗ |
| 7 | 2022 | Tom Sohn SVP, General Counsel & Secretary | 350.0K | 140.0K | 77.1K | 118.0K | — | 1.2K | 686.3K | 28.43% | ↗ |
| 8 | 2022 | Charlie Piscitello SVP, Chief People Officer | 330.0K | 132.0K | 78.3K | 124.1K | — | 1.2K | 665.6K | 30.41% | ↗ |
| 9 | 2021 | Vince Burgess President and CEO | 496.0K | 86.9K | 615.6K | 1.44M | — | 549.00 | 2.64M | 77.86% | ↗ |
| 10 | 2021 | Vince Burgess Former President and CEO | 496.0K | 86.9K | 615.6K | 1.44M | — | 549.00 | 2.64M | 77.86% | ↗ |
| 11 | 2021 | David Roman Chief Financial Officer | 300.8K | 135.8K | 500.0K | 699.9K | — | 242.7K | 1.88M | 63.85% | ↗ |
| 12 | 2021 | David Roman Former President and Chief Executive Officer | 300.8K | 135.8K | 500.0K | 699.9K | — | 242.7K | 1.88M | 63.85% | ↗ |
| 13 | 2021 | David Roman President and CEO | 300.8K | 135.8K | 500.0K | 699.9K | — | 242.7K | 1.88M | 63.85% | ↗ |
| 14 | 2021 | Steve McQuillan SVP, Regulatory, Clinical Affairs & Quality Assurance | 330.0K | 37.1K | 135.0K | 314.9K | — | 435.00 | 817.5K | 55.04% | ↗ |
| 15 | 2020 | Vince Burgess Former President and CEO | 392.1K | 188.8K | 400.0K | 5.59M | — | 435.00 | 6.57M | 91.16% | ↗ |
| 16 | 2020 | Vince Burgess President and CEO | 392.1K | 188.8K | 400.0K | 5.59M | — | 435.00 | 6.57M | 91.16% | ↗ |
| 17 | 2020 | John Barnickel Chief Commercial Officer | — | 207.7K | 120.0K | 1.97M | — | 363.00 | 2.55M | 81.99% | ↗ |
| 18 | 2020 | Gary W. Doherty Chief Financial Officer | — | 127.5K | 90.0K | 360.0K | — | 435.00 | 884.3K | 50.89% | ↗ |
| 19 | 2019 | Gary W. Doherty Chief Financial Officer | — | 60.0K | — | 692.0K | — | 435.00 | 1.06M | 65.41% | ↗ |
| 20 | 2019 | Vince Burgess President and CEO | 382.2K | 150.0K | — | — | — | 73.00 | 532.3K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Takeo Mukai | Chief Executive Officer & Chief Financial Officer | 809.0K | male |
ESG Rating
ESG Score History MEDICAL - DEVICES
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AFIB
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
